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Ⅰ．Introduction
 The treatment of rheumatoid arthritis （RA） has 
drastically changed over the past 20 years. The presence 
of anti-cyclic citrullinated peptide antibody and definite 
criteria［1］allow early diagnosis. The introduction 
of methotrexate （MTX） and biologic agents and a 
combination of disease-modifying anti-rheumatic drugs 
is essential for the treatment of RA［2-4］. In addition, 
aggressive treatment intervention and well-defined 
treatment targets have contributed to this change［5-7］.
 The effectiveness and safety of these new therapeutic 
agents are supported by numerous randomized 
controlled trials （RCTs）［3,4,8］. However, the diversity 
between patients who meet the inclusion criteria of these 
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Abstract
The introduction of new efficacious therapeutic agents and a treatment strategy aiming at early 
diagnosis and aggressive treatment intervention has drastically changed the treatment of rheumatoid 
arthritis （RA） over the past 20 years. Two large observational cohort studies, namely Institute of 
Rheumatology Rheumatoid Arthritis （IORRA）, Tokyo Women’s Medical University, and National 
database of rheumatic diseases by iR-net in Japan （NinJa）, have shown the current treatment trends in 
patients with RA in Japan. The present study aimed to investigate the current situation of the treatment 
of patients with RA at Chiba University Orthopaedic department. A cross-sectional observational study 
including 195 patients with RA （45 males/150 females; mean age: 64.8 years; mean disease duration: 
15.3 years） was conducted to address this question. Information on drug use, previous medical history, 
type of orthopedic surgeries related to RA, and laboratory data of the patients were examined. The 
rates of using methotrexate （mean dosage: 7.7 mg/week） and biologic agent were approximately 76% 
and 30%, respectively. Approximately 30% of patients had previously undergone orthopedic surgeries, 
and 16% underwent multiple surgeries. Total knee arthroplasty （TKA） was the most frequent surgery 
（22%）, and bilateral procedure was performed in almost half of these patients with TKA. However, 
further studies corroborating the findings regarding the treatment of RA at our institution are 
required.
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RCTs and those who receive the real treatment, as well 
as the long-term results of the treatment must be taken 
into consideration［9］. The use of data from prospective 
observational cohort studies may permit investigators to 
overcome such challenges［10,11］.
 In Japan, the use of MTX （maximum dosage: 8 
mg/week） for the treatment of patients with RA was 
approved in 1999. However, in 2011, this dosage was 
revised to 16 mg/week［12,13］. The use of tumor 
necrosis factor （TNF）-α inhibitor for the treatment 
of RA was approved in 2003 and that of other non-
TNF biologic agents was approved in 2008. The Japan 
College of Rheumatology （JCR） recommended the 
use of MTX as first-line therapy and additional or 
alternative use of biologic agents in cases of insufficient 
treatment efficacy, according to the European League 
Against Rheumatism （EULAR） recommendations［14］. 
In 2000, a large observational cohort study involving 
patients with RA was conducted at the Institute of 
Rheumatology, Tokyo Women’s Medical University 
（IORRA）. In 2002, another multicenter observational 
cohort  s tudy （NinJa） was conducted［15,16］. 
Previously, other regional cohort studies have also been 
conducted［17,18］. However, to our knowledge, no 
observational cohort studies have been conducted in 
Chiba. Therefore, this study aimed to investigate the 
current situation of the treatment of patients with RA at 
Chiba University Orthopaedic department.
Ⅱ．Patients and methods
 A cross-sectional observational study involving 
patients with RA, diagnosed according to the American 
College of Rheumatology （ACR）/EULAR classification 
criteria, was conducted［1］. A total of 195 patients （45 
males/150 females） treated at our institution in April 
2016 were included in the study. The research protocol 
of this study was following the Helsinki Declaration, 
approved by the Institutional Review Boards. （Research 
Ethics Committees of Graduate School of Medicine, 
Chiba University; the reference number #849） All 
of the attending physicians were the board-certified 
rheumatologists, and the treatment plans were decided 
by the conference. The mean age of the patients was 
64.8 years （standard deviation ［SD］: 11.8）, and the 
mean duration of disease was 15.3 years （SD: 11.2）. 
The information examined on drug use included the 
following: administration percentage and dosage of MTX 
and prednisolone （PSL）, administration percentage of 
salazosulfapyridine, immunosuppressive drugs including 
ciclosporin and tacrolimus, bucillamine, and biologic 
agents. Moreover, previous medical history and the type 
of orthopedic surgeries related to RA including implant 
arthroplasty, hand surgery, and cervical spine surgery 
were investigated. Laboratory data including C-reactive 
protein （CRP） level and erythrocyte sedimentation rate 
（ESR） were also examined.
Ⅲ．Results
 The administration rates of MTX （mean dosage: 
7.7 mg/week）, PSL （mean dosage: 4.8 mg/day）, and 
biologic agents were approximately 77%, 51%, and 
30%, respectively （Table 1, Fig. 1 and 2）. Reasons for 
discontinuation of the previous MTX administration 
included respiratory disorder （5 patients）, hepatopathy 
（2  patients）,  childbearing desire （2  patients）, 
thrombocytopenia （1 patient）, and fever induced by 
the drug （1 patient）. Other serious problem didn’t 
occur by the discontinuation and alteration of the drug. 
Previous accumulative orthopedic surgeries were 
Table 1　drug information
All patients n＝195
Patients using MTX, number （%） 148 （75.9）
Dosage of MTX, mg/week, mean±SD 7.7±3.4
Patients using PSL, number （%） 100 （51.3）
Dosage of PSL, mg/day, mean±SD 4.8±3.2
Patients using SASP, number （%） 68 （34.9）
Patients using ISD, number （%） 16 （8.2）
Patients using BUC, number （%） 11 （5.6）
Patients using biologic agents, number （%） 58 （29.7）
TNF-α inhibitor 44 （22.6）
IL-6 inhibitor 4 （2.1）
targeting T-cell 10 （5.1）
MTX, methotrexate; PSL, prednisolone; SASP, salazo-
sulfapyridine; ISD, immune-suppressive drug; BUC, 
bucillamine; TNF, tumor necrosis factor; IL, interleukin; 
SD, standard deviation; 
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reported in approximately 30% of patients, and total 
knee arthroplasty （TKA） was the most frequent surgery 
（22%） （Table 2）, and the number of TKA and total 
hip arthroplasty （THA） decreased after 2011 （Fig. 3）. 
Laboratory data showed that the mean CRP level and 
ESR were 0.41 and 15.6, respectively （Fig. 4）.
Ⅳ．Discussion
 Over the past 20 years, impressive improvements 
have been observed in the treatment of patients with 
RA. MTX has been reported to improve disease 
activity, function, and long-term outcomes including 
joint destruction and RA-associated mortality［19,20］. 
Currently, MTX is considered the anchor drug for the 
treatment of RA［14］. In the late 1990s and early 2000s, 
biologic agents were introduced for the treatment of 
RA. Currently, five TNF-α inhibitors, two interleukin-6 
inhibitors, and one T-cell targeting agent have been 
Fig. 1　Distribution of MTX dose （n＝150）
　Mean dose: 7.7mg （Male 8.7mg, Female 7.4mg）
Fig. 2　Distribution of PSL dose （n＝100）
　Mean dose: 4.8mg （Male 5.0mg, Female 4.7mg）
Fig. 3　Transition of RA related orthopedic surgery
　The number of each surgeries conducted in each 5 years 
were shown.
Fig. 4　Laboratory date
　CRP （Median: 0.1 mg/dl, Mean: 0.41 mg/dl）, ESR-60 
（Median: 13 mm/h, Mean: 15.6mm/h）Table 2　previous RA related orthopedic surgery
All patients n＝195
Patients with implant arthroplasty, 
number （%）
48 （24.6）
TKA, number （%） 42 （21.5）
Bilateral / contralateral, number 
（%）
19 （9.7） / 23 （11.8）
THA, number （%） 13 （6.7）
Bilateral / contralateral, number 
（%）
4 （2.1） / 9 （4.6）
TEA, number （%） 5 （2.6）
Bilateral / contralateral, number 
（%）
1 （0.5） / 4 （2.1）
Patients with hand surgery, number 
（%）
12 （6.2）
Patients with cervical spine surgery, 
number （%）
5 （2.6）
Patients with any surgery, number 
（%）
58 （29.7）
Patients with plural surgeries, number 
（%）
31 （16.4）
TKA, total knee arthroplasty; THA, total hip arthroplasty; 
TEA, total elbow arthroplasty;
30 Michiaki Miura et al.
approved in Japan as second choice for the management 
of patients with RA. Clinical, radiographical, and 
patient-based outcome evaluations revealed drastic 
improvements in disease activity and progression with 
these agents［21,22］. Treatment using these efficacious 
agents and a new therapeutic strategy consisting of early 
diagnosis and aggressive intervention has led to marked 
improvement in long-term outcomes for patients with 
RA［6,7］.
 In recent years, the administration of MTX and 
biologic agents has significantly increased. The IORRA 
study corroborated these findings: the proportion of 
patients receiving MTX was approximately 40% in 2002 
and approximately 75% in 2012. For biologic agents, 
the proportion of patients treated with these agents was 
0% in 2002 and vs. approximately 20% in 2012［23］. 
The NinJa study showed that the proportion of patients 
receiving MTX increased from 39.6% in 2004 to 63.8% 
in 2014, and the mean weekly dose increased from 
5.9 mg to 8.3 mg, respectively. Furthermore, it was 
reported that administration of biologic agents increased 
from 1.7% in 2004 to 27.4% in 2014［24］. The use 
of MTX is contraindicated during pregnancy and in 
those with hypersensitivity, serious infection, lymphatic 
disorder, hepatopathy, severe nephropathy, pleural and 
ascites fluid, and respiratory disorder［14］. Short-term 
and low-dose administration of glucocorticoids is also 
recommended by both the ACR and EULAR guidelines
［14］.
 The NinJa study showed that TKA and THA were 
the most frequent surgeries related to RA; however, 
their frequency significantly decreased from 30.1 and 
8.5 procedures per 1000 patients in 2004, respectively, 
to 11.5 and 6.1 procedures per 1000 patients in 2014, 
respectively. On the other hand, spine surgery showed a 
slow but significantly increasing trend due to operative 
indication, improved surgical technique, and use of 
developed instruments rather than RA severity［24］. 
The IORRA study showed that the number of implant 
arthroplasties gradually decreased since 2003 and 
stabilized around 2008. Surgeries involving fingers and 
wrists increased in number, and those procedures were 
mainly arthroplasties, which recently became available 
in Japan. An explanation for this, which was supported 
by the clinical results of surgery, is that patients are 
well-controlled by MTX/biologic agents and require 
an improved quality of life［23］. The decrease of knee 
and hip joint arthroplasties occurred also in this study. 
Although the distribution of each surgery was almost 
same as other registry in this study［24］, the percentage 
of the patient who underwent any surgery was higher 
than other registry. The reason might be that these 
patients were treated in Orthopaedic department.
 The current situation of the treatment of patients 
with RA at our institution was investigated. The 
administration rates and dosage of MTX, PSL, and 
biologic agents were similar to those reported in recent 
studies. TKA was the most frequent orthopedic surgery 
related to RA, and bilateral procedure was performed 
in almost half of the patients who underwent TKA. 
Laboratory data suggested that disease activity was 
nearly controlled with our treatment.
 A limitation of this study was the lack of data on 
patient visual analog scale （VAS） and the number of 
swollen/tender joints; thus, the disease activity could 
not be sufficiently evaluated. Another limitation is that 
this was the first observational study to investigate the 
situation of the treatment of patients with RA at our 
institution and no previous data are available to compare 
the findings of this study, so the changes of the trend 
of drug information or orthopedic surgeries were not 
proven.
 In conclusion, the current situation of the treatment 
of patients with RA at our institution was similar to that 
demonstrated by other Japanese studies investigating 
RA. Further longitudinal studies are warranted to assess 
this approach in detail and corroborate current findings.
Author contributions
 guarantor of integrity of the entire study: NJ, OS. 
study concepts and design: All authors. literature 
research: MM, HS, NJ. clinical studies: MM, HS. 
experimental studies / data analysis: All authors. 
statistical analysis: MM. manuscript preparation:  MM, 
HS. manuscript editing:  All authors.
31RA treatment in Chiba Univ
remission. J Rheumatol 30: 1138-46.
10） Singh G. （2001） Arthritis, rheumatism and aging 
medical information system post-marketing surveillance 
program. J Rheumatol 28: 1174-9.
11） Furst DE. （2004） Observational cohort studies and well 
controlled clinical trials-we need them both! J Rheumatol 
31: 1476-7.
12） Yamanaka H, Inoue E, Tanaka E, et al. （2007） Influence 
of methotrexate dose on its efficacy and safety in 
rheumatoid arthritis patients: evidence based on the 
variety of prescribing approaches among practicing 
Japanese rheumatologists in a single institute-based large 
observational cohort （IORRA）. Mod Rheumatol 17: 98-
105.
13） Seto Y, Tanaka E, Inoue E, et al. （2011） Studies of the 
efficacy and safety of methotrexate at dosages over 8 mg/
week using the IORRA cohort database. Mod Rheumatol 
21: 579-93.
14） Smolen JS, Landewé R, Breedveld FC, et al. （2014） 
EULAR recommendations for the management of 
rheumatoid arthritis with synthetic and biological disease-
modifying antirheumatic drugs: 2013 update. Ann Rheum 
Dis 73: 492-509. 
15） Matsuda Y, Singh G, Yamanaka H, et al. （2003） 
Validation of a Japanese version of the Stanford Health 
Assessment Questionnaire in 3,763 patients with 
rheumatoid arthritis. Arthritis Rheum 49: 784-8.
16） Yamanaka H, Tohma S. （2006） Potential impact of 
observational cohort studies in Japan on rheumatoid 
arthritis research and practice. Mod Rheumatol 16: 75-6.
17） Imanaka T, Shichikawa K, Inoue K, et al. （1997） 
Increase in age at onset of rheumatoid arthritis in Japan 
over a 30 year period. Ann Rheum Dis 56: 313-6.
18） Shichikawa K, Inoue K, Hirota S, et al. （1999） Changes 
in the incidence and prevalence of rheumatoid arthritis in 
Kamitonda, Wakayama, Japan, 1965-1996. Ann Rheum 
Dis 58: 751-6.
19） Choi HK, Herna’n MA, Seeger JD, Robins JM, Wolfe 
F. （2002） Methotrexate and mortality in patients with 
rheumatoid arthritis: a prospective study. Lancet 359: 
1173-7.
20） Pincus T, Sokka T, Kautiainen H. （2005） Patients seen 
for standard rheumatoid arthritis care have significantly 
better articular, radiographic, laboratory, and functional 
status in 2000 than in 1985. Arthritis Rheum 52: 1009-
19.
21） FC, Kalden JR, et al. （2000） Anti-Tumor Necrosis 
Factor Trial in Rheumatoid Arthritis with Concomitant 
Therapy Study Group. infliximab and methotrexate in the 
treatment of rheumatoid arthritis. Anti-Tumor Necrosis 
Factor Trial in Rheumatoid Arthritis with Concomitant 
Therapy Study Group. N Engl J Med 343: 1594-602.
22） Krishnan E, Lingala B, Bruce B, Fries JF. （2012） 
Disability in rheumatoid arthritis in the era of biological 
treatments. Ann Rheum Dis 71: 213-8.
23） Momohara S, Inoue E, Ikari K, Ochi K, Ishida O, Yano K, 
Sakuma Y, Yoshida S, Koyama T, et al. （2014） Recent 
Acknowledgement
 The co-author, NJ, received JSPS KAKENHI Grant 
Number 25870125 for this work.
Conflict of interest
 The other authors do not receive any financial 
support or other benefits from commercial sources for 
the work.
Reference
1 ） Aletaha D, Neogi T, Silman AJ III, et al. （2010）2010 
rheumatoid arthritis classification criteria: an American 
College of Rheumatology/European League Against 
Rheumatism collaborative initiative. Ann Rheum Dis 69: 
1580-8.
2 ） Visser K, van der Heijde D. （2009） Optimal dosage and 
route of administration of methotrexate in rheumatoid 
arthritis: a systematic review of the literature. Ann Rheum 
Dis 68: 1094-9.
3 ） Burmester GR, Mariette X, Montecucco C, et al. （2007） 
Adalimumab alone and in combination with disease-
modifying antirheumatic drugs for the treatment of 
rheumatoid arthritis in clinical practice: the Research in 
Active Rheumatoid Arthritis （ReAct） trial. Ann Rheum 
Dis 66: 732-9.
4 ） Strangfeld A, Hierse F, Kekow J, et al. （2009） Comparative 
effectiveness of tumour necrosis factor alpha inhibitors in 
combination with either methotrexate or leflunomide. Ann 
Rheum Dis 68: 1856-62.
5 ） Yamanaka H, Inoue E, Singh G, et al. （2007） Improvement 
of disease activity of rheumatoid arthritis patients from 
2000 to 2006 in a large observational cohort study IORRA 
in Japan. Mod Rheumatol 17: 283-9.
6 ） Smolen JS, Aletaha D, Bijlsma JW, et al. （2010） 
Treating rheumatoid arthritis to target: recommendations 
of an international task force. Ann Rheum Dis 69: 631-7.
7 ） Felson DT, Smolen JS, Wells G, et al. （2011） American 
College of Rheumatology/European League against 
Rheumatism provisional definition of remission in 
rheumatoid arthritis for clinical trials. Ann Rheum Dis 
70: 404-13.
8 ） Weinblatt ME, Polisson R, Blotner SD, et al. （1993） 
The effects of drug therapy on radiographic progression 
of rheumatoid arthritis: results of a 36-week randomized 
trial comparing methotrexate and auranofin. Arthritis 
Rheum 36: 613-9.
9 ） Sokka T, Pincus T. （2003） Most patients receiving 
routine care for rheumatoid arthritis in 2001 did not 
meet inclusion criteria for most recent clinical trials 
or American College of Rheumatology criteria for 
32 Michiaki Miura et al.
Surgery in Patients with Rheumatoid Arthritis: An 
Observational Cohort Study Using the Japanese National 
Database of Rheumatic Diseases. J Rheumatol 44: 1575-
82.
trends in orthopedic surgery aiming to improve quality of 
life for those with rheumatoid arthritis: data from a large 
observational cohort. J Rheumatol 41: 862-6.
24） Matsumoto T, Nishino J, Izawa N, et al. （2017） Trends 
in Treatment, Outcomes, and Incidence of Orthopedic 
